Join Growin Stock Community!

Glaukos corporationGKOS.US Overview

US StockHealthcare
(No presentation for GKOS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

GKOS AI Insights

GKOS Overall Performance

GKOS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

GKOS Recent Performance

-0.15%

Glaukos corporation

0.05%

Avg of Sector

-0.31%

S&P500

GKOS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

GKOS Key Information

GKOS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

GKOS Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, a three stents product that is designed for use as a standalone procedure in patients with refractory glaucoma; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in San Clemente, California.

Price of GKOS

GKOS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

GKOS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
13.78
PB Ratio
10.64
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
55.72%
Net Margin
-36.99%
Revenue Growth (YoY)
32.33%
Profit Growth (YoY)
-2.31%
3-Year Revenue Growth
26.19%
3-Year Profit Growth
24.39%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.23
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
13.78
PB Ratio
10.64
Price-to-FCF
-
Gross Margin
55.72%
Net Margin
-36.99%
Revenue Growth (YoY)
32.33%
Profit Growth (YoY)
-2.31%
3-Year Revenue Growth
26.19%
3-Year Profit Growth
24.39%

  • When is GKOS's latest earnings report released?

    The most recent financial report for Glaukos corporation (GKOS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating GKOS's short-term business performance and financial health. For the latest updates on GKOS's earnings releases, visit this page regularly.

  • What is the operating profit of GKOS?

    According to the latest financial report, Glaukos corporation (GKOS) reported an Operating Profit of -139.87M with an Operating Margin of -97.73% this period, representing a decline of 387.92% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is GKOS's revenue growth?

    In the latest financial report, Glaukos corporation (GKOS) announced revenue of 143.12M, with a Year-Over-Year growth rate of 35.66%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does GKOS have?

    At the end of the period, Glaukos corporation (GKOS) held Total Cash and Cash Equivalents of 94.65M, accounting for 0.11 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does GKOS go with three margins increasing?

    In the latest report, Glaukos corporation (GKOS) did not achieve the “three margins increasing” benchmark, with a gross margin of -1.1%%, operating margin of -97.73%%, and net margin of -93.4%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess GKOS's profit trajectory and future growth potential.

  • Is GKOS's EPS continuing to grow?

    According to the past four quarterly reports, Glaukos corporation (GKOS)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -2.33. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of GKOS?

    Glaukos corporation (GKOS)'s Free Cash Flow (FCF) for the period is 3.93M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 420.47% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.